ADR Ratio Change
September 19, 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
September 19, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for...
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 11, 2024 08:00 ET
|
Halberd Corp.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 09, 2024 09:31 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 04, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
September 04, 2024 07:46 ET
|
ANEW MEDICAL, INC.
Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
September 03, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Compass Therapeutics to Participate in Upcoming Investor Events
September 03, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Halberd Corp. Issues Letter to Shareholders
August 26, 2024 08:00 ET
|
Halberd Corp.
Halberd Corp. - Taking a Moment to Recenter Our Technical Progress